Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV patients with renal impairment

被引：0
|
作者：
Post, F. [1 ]
Andrade-Villanueva, J. [2 ]
Fisher, M. [3 ]
Winston, J. [4 ]
Liu, Y. [5 ]
Zhong, L. [5 ]
Cheng, A. [5 ]
Rhee, M. [5 ]
Szwarcberg, J. [5 ]
机构：
[1] Kings Coll Hosp London, London, England
[2] Hosp Civil Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico
[3] Brighton & Sussex Univ Hosp, Brighton, E Sussex, England
[4] Mt Sinai Sch Med, New York, NY USA
[5] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
HIV MEDICINE | 2014年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：115 / 115
页数：1
相关论文
共 50 条
  • [41] Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study
    Perez Stachowski, Javier
    Rial Crestelo, David
    Moreno Zamora, Ana
    Cabello, Noemi
    Ryan, Pablo
    Espinosa Aguilera, Nuria
    Bisbal, Otilia
    Vivancos Gallego, Maria Jesus
    Jose Nunez, Maria
    Troya, Jesus
    Dominguez, Montserrat
    Olalla Sierra, Julian
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (17)
  • [42] Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide
    Hortensia Álvarez
    Ana Mariño
    Nieves Valcarce
    Jesús García-González
    Helena Díaz-Cambre
    Josep M. Llibre
    Infection, 2019, 47 : 115 - 119
  • [43] Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
    Kaplun, Olga
    Psevdos, George
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (16) : 1180 - 1181
  • [44] Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
    Margot, Nicolas
    Cox, Stephanie
    Das, Moupali
    McCallister, Scott
    Miller, Michael D.
    Callebaut, Christian
    ANTIVIRAL THERAPY, 2017, 22 (05) : 443 - 446
  • [45] Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment-na ve HIV-1-infected patients
    Rockstroh, J.
    DeJesus, E.
    Henry, K.
    Molina, J.
    Gathe, J.
    Wei, X.
    Fordyce, X.
    Rhee, M.
    Szwarcberg, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 23 - 23
  • [46] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet for HIV-1 Infection Treatment
    Olin, Jacqueline L.
    Spooner, Linda M.
    Klibanov, Olga M.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (12) : 1671 - 1677
  • [47] Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide
    Alvarez, Hortensia
    Marino, Ana
    Valcarce, Nieves
    Garcia-Gonzalez, Jesus
    Diaz-Cambre, Helena
    Llibre, Josep M.
    INFECTION, 2019, 47 (01) : 115 - 119
  • [48] Comment on: Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection
    Ambrosioni, Juan
    Mosquera, Maria M.
    Miro, Jose M.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (05) : 1548 - 1549
  • [49] Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients
    Biagi, M.
    Badowski, M. E.
    Chiampas, T.
    Young, J.
    Patel, M.
    Vaughn, P.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2017, 28 (08) : 766 - 772
  • [50] Neuropsychiatric, clinical and laboratory changes in patients prospectively switching from elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide to bictegravir/emtricitabine/tenofovir alafenamide
    Tiraboschi, J.
    Prieto, P.
    Saumoy, M.
    Silva, A.
    Imaz, A.
    Scevola, S.
    Fernandez-Olivares, G.
    Navarro-Alcaraz, A.
    Piatti, C.
    Podzamczer, D.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 79 - 80
12345